Dr. Blanka Kaplan, MD
Pediatrics (Pediatric Allergy/Immunology Physician)
Sch - Dept Of Allergy Immunology, 865 Northern Boulevard
Great Neck, NY 11021
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 131
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Allergy/Immunology Physician primary
NY license 210998
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
Medical groups
- North Shore-Lij Medical PC (6,440 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 131
- Services billed
- 2,092
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 1,037 | 25 |
| Test for allergy using combination of methods with drug or biological | 126 | 19 |
| Established patient office or other outpatient visit, 30-39 minutes | 93 | 70 |
| Insertion of needle into vein for collection of blood sample | 51 | 41 |
| New patient office or other outpatient visit, 45-59 minutes | 31 | 31 |
| Established patient office or other outpatient visit, 20-29 minutes | 25 | 24 |
| Test for allergy using ingested items, initial 2 hours | 24 | 23 |
| Test to measure expiratory airflow and volume | 22 | 20 |
| New patient office or other outpatient visit, 30-44 minutes | 22 | 22 |
| Test to measure the level of nitric oxide gas | 20 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azelastine Hcl Other prescribers in Great Neck, NY | 31 |
| Hizentra (immun glob g(igg)/pro/iga 0-50) | 25 |
| Fluticasone Propionate Other prescribers in Great Neck, NY | 18 |
| Dupixent Pen (dupilumab) Other prescribers in Great Neck, NY | 17 |
| Cromolyn Sodium | 16 |
| Montelukast Sodium Other prescribers in Great Neck, NY | 16 |
| Levocetirizine Dihydrochloride Other prescribers in Great Neck, NY | 13 |
| Xolair (omalizumab) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $162 in total to this clinician.
| GlaxoSmithKline, LLC. | $92.70 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $68.97 |
| Food and Beverage | $162 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $87,070 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Sanofi US Services Inc. · Active, not recruiting · NCT06834347 - EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Genzyme Corporation · Completed · NCT04998604 - A randomised, double-blind, parallel group phase iii study to assess t
GlaxoSmithKline, LLC. - Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04959448
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.